Synonyms: compound 68 [WO2010002845A2] | HMPL-813 | HMPL813
Compound class:
Synthetic organic
Comment: Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor that is under investigation for potential to treat solid tumours in China. Epitinib appears to be a 'pseudo' INN. As of July 2021 there had been no submission to the WHO for the INN. The chemical structure is claimed in patent WO2010002845A2 [1].
|
|
Bioactivity Comments |
Patent WO2010002845A2 contains the statement 'results show that all of Compounds 1-170 inhibited EGFR activity. Their IC50 values ranged from 0.001 μM to 10 μM' [1], so does not specify an inhibitory value for epitinib (which is example 68). |